Effects of chronic treatment with classic and newer antidepressants and neuroleptics on the activity and level of CYP2D in the rat brain

Polish Journal of Pharmacology

Volumn 56, Issue 6, 2004, Pages 857-862

  Haduch, Anna ^a   Wójcikowski, Jacek ^a   Daniel, Władysława A ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Brain; CYP2D; Imipramine; Mirtazapine; Risperidone; Thioridazine

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2D; CYTOCHROME P450 2D4; ETHYLMORPHINE; GLUCOSE 6 PHOSPHATE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; IMIPRAMINE; MIRTAZAPINE; MORPHINE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RISPERIDONE; THIORIDAZINE; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN METABOLISM; BRAIN MICROSOME; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME REGULATION; IN VITRO STUDY; LONG TERM CARE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BRAIN; CYTOCHROME P-450 ENZYME SYSTEM; DRUG ADMINISTRATION SCHEDULE; MALE; RATS; RATS, WISTAR;

EID: 14244259595     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Bensoussan C, Delaforge M, Mansuy D: Particular ability of cytochrome P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem Pharmacol, 1995, 49, 591-602.
2. Daniel WA, Haduch A, Wójcikowski J: Inhibition and possible induction of rat CYP2D after short- and long-term treatment with antidepressants. J Pharm Pharmacol, 2002, 54, 1545-1552.
3. Daniel WA, Haduch A, Wójcikowski J: Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo. Possible involvement of different mechanisms. Eur Neuropsychopharmacol, 2005, 15, 103-110.
4. Glare PA, Walsh TD, Pippenger CE: A simple, rapid method for the simultaneous determination of morphine and its principal metabolites in plasma using high-performance liquid chromatography and fluorometric detection. Ther Drug Monit, 1991, 13, 226-232.
5. Gutierrez-Correa J, Fairlamb AH, Stoppani AO: Inactivation of Trypanosoma cruzi trypanothione reductase by phenothiazine cationic free radicals. Rev Argent Microbiol, 2001, 33, 36-46.
6. Gutierrez-Correa J, Fairlamb AH, Stoppani AO: Trypanosoma cruzi trypanothione reductase is inactivated by peroxidase-generated phenothiazine cationic radicals. Free Radic Res, 2001, 34, 363-378.
7. Gutierrez-Correa J, Stoppani AO: Mycloperoxidase-generated phenothiazine cation radicals inactivate Trypanosoma cruzi dihydrolipoamide dehydrogenase. Rev Argent Microbiol, 2002, 34, 83-94.
8. Hiroi T, Chow T, Imaoka S, Funae Y: Catalytic specificity of CYP2D isoforms in rat and human. Drug Metab Dispos, 2002, 30, 970-976.
9. Hiroi T, Imaoka S, Funae Y: Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun, 1998, 249, 838-843.
10. Hiroi T, Kishimoto W, Chow T, Imaoka S, Igarashi T, Funae Y: Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology, 2001, 142, 3901-3908.
11. Kishimoto W, Hiroi T, Shiraishi M, Osada M, Imaoka S, Kominami S, Igarashi T, Funae Y: Cytochrome P450 2D catalyzes steroid 21-hydroxylation in the brain. Endocrinology, 2003, 145, 699-705.
12. Masubushi Y, Igarashi S, Suzuki T, Horie T, Narimatsu S: Imipramine-induced inactivation of cytochrome P450 2D enzyme in rat liver microsomes in relation to covalent binding of its reactive intermediate. J Pharmacol Exp Ther, 1996, 279, 724-731.
13. Masubushi Y, Takahashii C, Fujio N, Horie T, Suzuki T, Imaoka S, Funae Y, Narimatsu S: Inhibition and induction of cytochrome P450 isoenzymes after repetitive administration of imipramine in rats. Drug Metab Dispos, 1995, 23, 999-1003.
14. Miksys S, Rao Y, Sellers EM, Kwan M, Mendis D, Tyndale RF: Regional and cellular distribution of CYP2D subfamily members in rat brain. Xenobiotica, 2000, 30, 547-564.
15. Miksys SL, Tyndale RF: Drug-metabolizing cytochrome P450s in the brain. J Psychiatry Neurosci, 2002, 27, 406-415.
16. Thompson CM, Capdevila JH, Strobel HW: Recombinant cytochrome P450 2D18 metabolism of dopamine and arachidonic acid. J Pharmacol Exp Ther, 2000, 294, 1120-1130.
17. Thompson CM, Kawashima H, Strobel HW: Isolation of partially purified P450 2D18 and characterization of activity toward the tricyclic antidepressants imipramine and desipramine. Arch Biochem Biophys, 1998, 359, 115-121.
18. Tyndale RF, Li Y, Li N-Y, Messina E, Miksys S, Sellers EM: Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. Drug Metab Dispos, 1999, 27, 924-930.
19. Wyss A, Gustafsson JA, Warner M: Cytochromes P450 of the 2D subfamily in rat brain. Mol Pharmacol, 1995, 47, 1148-1155.
20. Xu BQ, Aassmundstad TA, Bjørneboe A, Christofersen AS, Mørland J: Ethylmorphine O-deethylation in isolated rat hepatocytes. Biochem Pharmacol, 1995, 49, 453-460.
21. Yu A-M, Idle JR, Byrd LG, Krausz KW, Küpfer A, Gonzales FJ: Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics, 2003, 13, 173-181.